Post-transcriptional downregulation of sarcolipin mRNA by triiodothyronine in the atrial myocardium  by Minamisawa, Susumu et al.
FEBS Letters 580 (2006) 2247–2252Post-transcriptional downregulation of sarcolipin mRNA
by triiodothyronine in the atrial myocardium
Susumu Minamisawaa,*, Nobuyuki Uemuraa,b, Yoji Satoc, Utako Yokoyamaa,
Teruhide Yamaguchic, Kazuhide Inouec, Masamichi Nakagomea, Yunzhe Baia, Hideaki Horia,
Mitsuyuki Shimizub, Seibu Mochizukib, Yoshihiro Ishikawaa,d
a Department of Physiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
b Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku,
Tokyo 105-8461, Japan
c Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, 1-18-1 Kami-yoga, Setagaya-ku, Tokyo 158-8501, Japan
d Departments of Medicine (Cardiology) and Cell Biology and Molecular Medicine, Cardiovascular Research Institute, New Jersey Medical School,
University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue, MSB G611, Newark, NJ 07101, USA
Received 15 February 2006; accepted 9 March 2006
Available online 20 March 2006
Edited by Veli-Pekka LehtoAbstract Thyroid hormone-mediated positive cardiotropic ef-
fects are diﬀerently regulated between the atria and ventricles.
This regulation is, at least in part, dependent on sarcoplasmic
reticulum (SR) proteins. Sarcolipin, a homologue of phospho-
lamban, has been recently identiﬁed as an atrium-speciﬁc SR
protein. The expression of sarcolipin mRNA was signiﬁcantly
decreased in the atria of mice with hyperthyroidism and in
3,5,3 0-triiodo-L-thyronine-treated neonatal rat atrial myocytes.
Promoter activity and mRNA stability analyses revealed that
thyroid hormone post-transcriptionally downregulated the
expression of sarcolipin mRNA. The atrium-speciﬁc eﬀect of
thyroid hormone may occur in part through the regulation of
atrial sarcolipin gene expression.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Thyroid hormone plays an important role in normal cardio-
vascular development and exerts positive inotropic, lusitropic,
and chronotropic eﬀects on the heart [1]. These eﬀects are med-
iated in part by regulating the transcription of the genes encod-
ing proteins involved in Ca2+ cycling, ion transport, b-Abbreviations: ANF, atrial natriuretic factor; CSQ2, cardiac calseques-
trin; EDD, end-diastolic left ventricular dimension; ESD, end-systolic
left ventricular dimension; %FS, percent fractional shortening; GAP-
DH, glyceraldehyde-3-phosphate dehydrogenase; IVS, interventricular
wall thickness; LVPW, left ventricular posterior wall thickness;MLC2a,
atrial myosin light chain 2; NCX1, cardiac sodium calcium exchanger;
PLN, phospholamban; RT-PCR, reverse transcription polymerase
chain reaction; RyR2, cardiac ryanodine receptor; SERCA, SR
Ca2+-ATPase; SLN, sarcolipin; SR, sarcoplasmic reticulum; T3, 3,5,
3 0-triiodo-L-thyronine; TR, thyroid hormone receptor; TRE, thyroid
hormone response element
*Corresponding author. Fax: +81 45 788 1470.
E-mail address: sminamis@med.yokohama-cu.ac.jp (S. Minamisawa).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.03.032adrenergic signaling, and myoﬁbrillar organization. In addi-
tion to its physiological role, the excess of thyroid hormone,
or the state of ‘‘hyperthyroidism’’, often induces pathological
changes in the heart such as cardiac hypertrophy, sinus tachy-
cardia and atrial arrhythmias including atrial ﬁbrillation. The
prevalence of atrial arrhythmias is much higher than that of
ventricular arrhythmias in patients with hyperthyroidism, indi-
cating that the atrial myocardium is more susceptible to
rhythm disturbance by the excess of thyroid hormone than
the ventricular myocardium. In this regard, it has been known
that the responses to thyroid hormone diﬀer between the atria
and ventricles [2–4]. Kaasik et al. demonstrated that thyroid
hormone activated sarcoplasmic reticulum (SR) Ca2+ ATPase
(SERCA) more in the atria than in the ventricles [3]. Shenoy
et al. showed that the Ca2+ transporter proteins were diﬀer-
ently regulated in the atria and the ventricles [4]. Several recent
studies have suggested that abnormal intracellular Ca2+
homeostasis and perturbations in Ca2+ cycling play an impor-
tant role in atrial ﬁbrillation-induced atrial remodeling [5,6].
Therefore, the diﬀerential eﬀect of thyroid hormone on the
proteins involved in Ca2+ cycling may account for the occur-
rence of atrial rather than ventricular arrhythmias.
We have found that sarcolipin (SLN), a homologue of phos-
pholamban (PLN), is speciﬁcally expressed in the atrial myo-
cardium and skeletal muscle, but not in the ventricular
myocardium [7]. SLN interacts with SERCA and regulates
excitation–contraction coupling in the atrial and skeletal mus-
cles [8]. Accordingly, SLN may play an important role in char-
acterizing the chamber-speciﬁc physiological properties of the
atria. The atrial chamber-speciﬁc expression of SLN could
be primarily regulated at the transcriptional level. Our previ-
ous studies have demonstrated that SLN mRNA expression
is increased during development, and decreased by hypertro-
phic remodeling of the atria [7,9] as well as in patients with at-
rial ﬁbrillation [10]. However, the eﬀect of thyroid hormone on
the transcriptional regulation of the SLN gene in the heart has
not been investigated, although thyroid hormone is known to
regulate the transcription of the SR genes such as PLN and
cardiac SERCA2 isoform (SERCA2a) in the heart [11–13].
In the present study, we examined the eﬀect of thyroid hor-
mone on the transcription of SLN gene in the atrial tissue
and myocytes.blished by Elsevier B.V. All rights reserved.
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2.1. Animals
All treatments were approved by the Animal Protocol Committee
of Yokohama City University School of Medicine. Hyperthyroidism
was induced in ddY mice (Nippon SLC Inc.) at 6.5 weeks of age
(n = 5) by intraperitoneally injecting 3,5,3 0-triiodo-L-thyronine (T3)
at a dose of 2 lg/g body weight/day for 4 weeks. Hypothyroidism
was induced in ddY mice at 3 weeks of age (n = 5) by feeding the ani-
mals with a 0.05% 5-propyl-2-thiouracil (PTU)-containing water for 8
weeks. Non-treated (euthyroid) mice (n = 5) were bred for the same
period.
2.2. Transthoracic echocardiography
Transthoracic echocardiography was performed as previously de-
scribed [14].
2.3. Cell culture and stimulation with T3
Neonatal rat atrial myocytes were prepared as the same method de-
scribed previously for neonatal rat ventricular myocytes [15]. Cardio-
blast H9C2 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 1% fetal calf serum (FCS) for 7 days after
conﬂuence. Neonatal rat atrial myocytes and H9C2 cells were treated
with 1 nM of T3 for 24 h, and were then collected.
2.4. Northern blot and quantitative reverse transcription polymerase
chain reaction (RT-PCR) analyses
Isolation of total RNA and Northern blot analysis were performed
as previously described with modiﬁcation [7,9,16]. Mouse cDNA
probes including the SLN gene were used as reported previously [9].
The quantitative RT-PCR was performed by using SYBR Green
PCR reagents (Applied Biosystems) as previously described [10]. The
forward and reverse primer sequences of SLN were 5 0-CTGAGG-
TCCTTGGTAGCCTG-30 and 5 0-GGTGTGTCAGGCATTGTGAG-
30, respectively.
2.5. Cloning of mouse sarcolipin promoter
During the present study was prepared, the genomic sequence of
mouse chromosome 9 including 5 0 ﬂanking sequence of the SLN gene
has been published (NCBI Accession No.: NT_039474). The primers
for PCR ampliﬁcation of 5 0 ﬂanking sequence of the SLN gene were
designed as based on the nucleotide sequence (forward: 5 0-CAGCT-
AACCAGGCACAACAA-30, reverse: 5 0-CACTCAGGCTACCAAG-
GACC-30). A 2299-bp fragment between 2237 of the 5 0 ﬂanking se-
quence and +62 of the non-coding exon 1 of the SLN gene was
ampliﬁed and was subcloned into a pDrive vector (Qiagen). The nucle-
otide sequence was conﬁrmed by direct DNA sequencing.
2.6. Promoter activity assay
The 2299-bp and fragments of the SLN promoter region was cloned
into the promoter-less ﬁreﬂy luciferase expression vector, pGL3-Basic
(Promega). This construct was named 2237/SLNluc. A shorter con-
struct, 563/SLNluc, containing 563 upstream nucleotides from the
putative transcriptional start site was made by self-ligation after diges-
tion of MluI restriction enzyme. Neonatal rat atrial myocytes were
incubated with serum-free medium for 24 h and then they were tran-
siently co-transfected with 300 ng of each SLN promoter luciferase test
plasmid and 75 ng of phRL-TK control plasmid (Promega), using Fu-
Gene 6 (Roche). Three hours after the transfection, the myocytes were
incubated with or without T3 (1 nM) for 24 h, and the luciferase activ-
ity was measured with Dual-Luciferase Reagents (Promega).
2.7. mRNA stability assay
To determine whether T3 alters SLN mRNA stability, H9C2 cells
were treated with 5 lg/ml actinomycin D, a blocker for transcription,
in the presence or absence of 1 nM T3 for up to 8 h. At the indicated
times, total cellular RNA was prepared and analyzed by quantitative
RT-PCR analysis.
2.8. SERCA activity
SERCA activity was measured as previously described [7].2.9. Statistics
Data are expressed as means ± S.E.M. Diﬀerences were considered
signiﬁcant at P < 0.05 (one- or two-way ANOVA with Student–New-
man–Kuel’s post hoc test).3. Results
3.1. The expression of SLN mRNA was decreased in the atria of
hyperthyroid mice
Serum concentrations of free triiodothyronine were >32.6,
2.75 ± 0.17, and 1.71 ± 0.12 pg/ml in hyperthyroid, euthyroid
and hypothyroid mice, respectively. Hyperthyroidism was
associated with signiﬁcant increases in the left ventricle/body
weight ratio and the atria/body weight ratio when compared
with euthyroid mice (Fig. 1A and B). Transthoracic echocardi-
ography revealed that heart rate, LV chamber size and LV ven-
tricular wall thickness were signiﬁcantly increased in
hyperthyroid mice when compared with those in euthyroid
mice (Fig. 1C–E). However, these parameters except heart rate
were not diﬀerent between hypothyroid and euthyroid mice
(Fig. 1). Percent fractional shortening (%FS) was not diﬀerent
among three groups (Fig. 1F).
The expression of SLN mRNA was signiﬁcantly decreased
in the atria of the hyperthyroid mice when compared with both
euthyroid and hypothyroid mice (Fig. 2A and B). The expres-
sion of SLN mRNA was slightly higher in the hypothyroid at-
ria than the euthyroid atria, although the diﬀerence did not
reach statistical signiﬁcance. No SLN transcript was detected
in the ventricles of both hyperthyroid and hypothyroid mice
(data not shown). The expression levels of PLN, SERCA2a,
cardiac sodium calcium exchanger (NCX1), RyR2, CSQ2,
ANF and atrial myosin light chain 2 (MLC2a) mRNAs were
also examined in these atria. We found that the expression le-
vel of PLN (Fig. 2C) and MLC2a (data not shown) RNAs
were signiﬁcantly decreased in the hyperthyroid mice.
SERCA activity in the hyperthyroid atria (n = 4) was signif-
icantly higher than that in the euthyroid atria (n = 4)
(590 ± 66 nmol/mg protein/min and 270 ± 66 nmol/mg pro-
tein/min, respectively). SR Ca2+ ATPase activity was much
higher in the atria than that in the ventricles (hyperthyroid:
142 ± 25 nmol/mg protein/min; euthyroid: 56 ± 20 nmol/mg
protein/min).
3.2. Thyroid hormone downregulated the expression of SLN in
neonatal rat atrial myocytes
To avoid a secondary eﬀect of thyroid state-mediated hemo-
dynamics on the expression of SLN mRNA, we examined the
eﬀect of T3 in cultured neonatal rat atrial myocytes. T3 de-
creased the expression of SLN mRNA by 20% (P < 0.05) in
neonatal rat atrial myocytes that did not exhibit a signiﬁcant
enlargement in size, whereas T3 increased the expression levels
of SERCA2a and NCX1 mRNAs by 80% (P < 0.001) and 37%
(P < 0.01), respectively (Fig. 3A and B). PLN mRNA was
undetectable in neonatal rat atrial myocytes in our experi-
ments.
3.3. Thyroid hormone treatment did not suppress the SLN
transcriptional activity, but accelerated SLN mRNA
degradation
Transfection with 2237/SLNluc or 563/SLNluc resulted
in a 40-fold increase in transcriptional activity in neonatal
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Fig. 1. Cardiac morphology and function in hyperthyroid and hypothyroid mice. (A) Left ventricle/body weight ratio; (B) atria/body weight ratio;
(C) heart rate; (D) left ventricular end-diastolic diameter (EDD); (E) left ventricular posterior wall thickness (LVPW); (F) percent fractional
shortening (%FS). The left ventricle/body weight ratio and the atria/body weight ratio were signiﬁcantly increased in hyperthyroid mice.
Transthoracic echocardiography revealed that heart rate, EDD and LVPW were signiﬁcantly increased in hyperthyroid mice, whereas %FS was not
diﬀerent among three groups.
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control plasmid. The transcriptional activity, however, was
not changed in the presence or absence of T3 (Fig. 4A). We
then examined the eﬀect of T3 on SLN mRNA stability in
H9C2 cells in the presence or absence of T3. The decay of
SLN mRNA levels was greater in H9C2 cells in the presence
of T3 for 4 and 8 h after actinomycin D treatment (Fig. 4B).4. Discussion
The present in vivo and in vitro studies demonstrated that
thyroid hormone decreased the expression of SLN mRNA in
the atrial tissue and myocytes. To our knowledge, this is the
ﬁrst report showing that the expression of the SLN gene are
regulated by thyroid hormone. Thyroid hormone binds to
high-aﬃnity nuclear receptors that consist of thyroid hormone
response elements (TREs), resulting in activating or repressing
gene transcription. The thyroid hormone repressed-genes gen-
erally contain one or more negative TREs. In the present
study, we found four putative TREs in the SLN promoter re-
gion between 2237 of the 5 0 ﬂanking sequence and +62 of the
partial non-coding exon 1 of the SLN gene. However, our data
indicated that these TREs were not responsible for the sup-
pressive SLN transcription by thyroid hormone. Instead, we
found that thyroid hormone accelerated the decay of the
expression of SLN mRNA, suggesting that thyroid hormonealtered SLN mRNA stability and thus increased its degrada-
tion. In this regard, a number of studies have demonstrated
that thyroid hormone post-transcriptionally downregulates
the expression of several genes [17,18]. The in vitro study de-
scribed here indicated that T3 (1 nM) was suﬃcient to decrease
the SLN transcripts in cultured neonatal rat atrial myocytes,
where the stresses such as tachycardia and increased afterload
due to ventricular hypertrophy were eliminated. Therefore, we
think that the excess of thyroid hormone directly downregu-
lates the expression of SLN mRNA. However, the depressing
eﬀect of T3 on SLN mRNA levels on in vitro neonatal atrial
cardiomyocytes was much less pronounced than the in vivo at-
rial tissues. Accordingly, we have demonstrated that local pres-
sure overload or atrial ﬁbrillation decreases the expression of
SLN mRNA in the atria [9,10]. Since the hyperthyroid mice
investigated here displayed cardiac hypertrophy and sinus
tachycardia, we postulated that these stresses augmented the
decrease in the expression of SLN mRNA in the in vivo atria.
On the other hand, the present study demonstrated that the
hypothyroid mice exhibited no change in cardiac morphology
and function except slower heart rates. Accordingly, we found
that the expression of SLN mRNA was not signiﬁcantly in-
creased in the atria of hypothyroid mice. We assume that the
expression of SLN mRNA would reach the maximal level in
the adult atria even in the euthyroid state and that a decrease
in thyroid hormone does not enhance SLN mRNA stability.
There is an alternative possibility that the intensity and dura-
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Fig. 2. The expression of SLN mRNA was decreased in the atrial myocardium of the hyperthyroid mice. (A) The raw data of the expression of SLN
mRNA by Northern blot analysis. Ten lg of total RNA was loaded per lane. (B–D) The summary of Northern blot analyses. The expression levels of
SLN and PLN mRNAs were signiﬁcantly decreased in the atria of the hyperthyroid mice (Hyper-) when compared with euthyroid and hypothyroid
mice (Eu- and Hypo-, respectively). The expression levels of SERCA2a mRNA were not diﬀerent between three groups. Each signal intensity was
standardized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used as an internal control. The data are presented as means ± S.E.M.
**P < 0.01; ***P < 0.001; ns, not signiﬁcant.
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expression of SLN mRNA in the present study.
A large body of evidence has indicated that thyroid hormone
plays an important role in the expression of the SR Ca2+ genes
[19–21]. It has been known well that PLN is downregulated by
thyroid hormone, which was conﬁrmed in the atria by the pres-
ent study. The downregulation of PLN mRNA contributes to
the positive inotoropic eﬀects mediated by thyroid hormone
treatment. Like PLN, SLN also inhibits SERCA2a function
and reduces SR Ca2+ stores [22]. Accordingly, the atrial tissues
may be more sensitive to the stimulation of thyroid hormone
than the ventricular tissues because of a decrease in SLN
expression in addition to a decrease in PLN. It is of great inter-
est that the downregulation of SLN mRNA by thyroid hor-
mone would result in a decrease in SLN protein in the atria.
In the present study, we could not show it, because it is diﬃcult
to obtain a SLN antibody probably due to the very short cyto-
plasmic region of the structure. Further investigation will be
required to clarify whether thyroid hormone-mediated down-
regulation of SLN mRNA increases Ca2+ uptake in the atria
and thus function.
In conclusion, the SLN transcripts in the atrial tissue and
myocytes were post-transcriptionally downregulated by thy-
roid hormone. The atrium-speciﬁc eﬀect of thyroid hormone
may occur, at least in part, through the regulation of atrial
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